Your search for major depressive disorder returned 168 results

AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.

A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.

More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.

The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.

The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.

Dr Amit Akirov examines the evidence suggesting associations between migraine and major depressive disorder (MDD).

This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.

Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.

Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

While the relationship between current mood state and cognitive impairment is unclear, more severe depression has been linked to greater impairment.

The degree of overlap between MDD and burnout is unclear. However, dysfunctional sleep patterns are known risk factors for both conditions.

The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.

Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.

Migraine with active headache may predict other painful physical symptoms in patients with major depressive disorder.

Researchers suggest that improvement in cognitive function should be a goal for major depressive disorder because their data showed little improvement in the cognitive abilities of patients with major depression after treatment with psychological interventions.

Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.

Migraine was more significantly associated with pain or muscle soreness than anxiety disorders in patients with depression.

Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.

Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.

Cognitive impairment in individuals with major depressive disorder should be treated as a primary problem.

Researchers compared how patients experiencing a major depressive episode and control participants perceived contrast patterns.

The percentage of adults with mental health issues increased, as did the percentage reporting that they needed but did not receive help.

Researchers from Dalhousie University in Canada searched publication databases through September of 2020 for articles on ADHD, attention deficit disorder, bipolar disorder, and affective psychosis.

Researchers set out to evaluate whether propranolol efficacy is greater in people with comorbid migraine compared with those without migraine.

Recently updated diagnostic criteria for fibromyalgia that reduce the underdiagnosis in men had not been implemented during these studies.

With little being known about the predictors or moderators of dTMS outcome for OCD, this study sought to examine if several theoretically relevant variables may predict and moderate treatment effects including OCD symptom severity, functional impairment, co-occurring depressive symptoms, age, gender, age of OCD onset, and family history of OCD.

While statins have both good and bad outcomes in the realm of neuropsychiatry, researchers looked at the possible associations with statins and suicidality, depression, anxiety, and seizures.